Exenatide

The FDA approved a generic version of the GLP-1 receptor agonist liraglutide to improve glycemic control for people with type 2 diabetes, according to a press release from the agency.

BOSTON — From 2019 to 2023, insurance covered GLP-1 receptor agonist prescriptions at a Texas hospital for less than 70% of young people with type 2 diabetes and less than 40% of those with obesity.

Semaglutide conferred greater reductions in HbA1c and body weight among adults with type 2 diabetes than other GLP-1 receptor agonists, according to findings from a systematic review and meta-analysis.

GLP-1 receptor agonists may reduce the number of postprandial hypoglycemia episodes after bariatric surgery, but more research is needed to guide use in practice, according to a systematic review published in Obesity.

Researchers have found 36 cases of acute cholecystitis associated with the use of GLP-1 receptor agonists in the U.S., according to findings from the FDA Adverse Event Reporting System published in JAMA Internal Medicine.

Teens with severe obesity who lost weight maintained more of their weight loss with use of a GLP-1 receptor agonist plus lifestyle therapy compared with lifestyle therapy alone, according to study findings published in Obesity.

Combination therapy with a GLP-1 receptor agonist and an SGLT2 inhibitor may provide better weight-loss benefits than a single agent for women with polycystic ovary syndrome and obesity, according to study data.

The FDA approved the GLP-1 receptor agonist exenatide for children aged 10 to 17 years with type 2 diabetes, the first once-weekly injectable approved for pediatric use in the United States, according to an industry press release.

Adolescents with type 2 diabetes were more likely to achieve HbA1c targets after 24 weeks of once-weekly exenatide compared with placebo, with trends observed toward decreased fasting plasma glucose and reduced body weight, data show.

Adults with type 1 diabetes on multiple daily injection therapy saw no benefit in glycemic measures when adding on preprandial injections of short-acting exenatide, according to findings from a phase 2a study published in The Lancet Diabetes & Endocrinology.